-transparent.png){kind=logo}
In vivo suppression of neovascularization by in situ administration of human recombinant interferon alpha 2a (hrIFN-alpha 2a) was tested on the chick embryo area vasculosa (AV). Methylcellulose discs, each containing 5 IU of hrIFN-alpha 2a were implanted onto the AV at Hamburger-Hamilton (HH) stage 13, and inhibition of blood vessel growth was morphometrically evaluated between HH stages 20 and 27. Our results show: (i) a decreased extent of the AV; (ii) a decreased AV total vessel length; (iii) modified percent ratios of different classes of AV vessels having a definite length. The observed effects of treating with hrIFN-alpha 2a are likely attributable to inhibition of endothelial cell proliferation.
D Ribatti, and
A Vacca, and
M Iurlaro, and
R Ria, and
L Roncali, and
F Dammacco
October 1990,
Journal of anatomy,
D Ribatti, and
A Vacca, and
M Iurlaro, and
R Ria, and
L Roncali, and
F Dammacco
June 1995,
Journal of anatomy,
D Ribatti, and
A Vacca, and
M Iurlaro, and
R Ria, and
L Roncali, and
F Dammacco
December 1993,
Journal of anatomy,
D Ribatti, and
A Vacca, and
M Iurlaro, and
R Ria, and
L Roncali, and
F Dammacco
January 1990,
Leukemia research,
D Ribatti, and
A Vacca, and
M Iurlaro, and
R Ria, and
L Roncali, and
F Dammacco
May 1989,
Journal of pharmacobio-dynamics,
D Ribatti, and
A Vacca, and
M Iurlaro, and
R Ria, and
L Roncali, and
F Dammacco
January 1988,
Haematologica,
D Ribatti, and
A Vacca, and
M Iurlaro, and
R Ria, and
L Roncali, and
F Dammacco
September 1992,
Clinical and experimental immunology,
D Ribatti, and
A Vacca, and
M Iurlaro, and
R Ria, and
L Roncali, and
F Dammacco
January 1993,
Acta oncologica (Stockholm, Sweden),
D Ribatti, and
A Vacca, and
M Iurlaro, and
R Ria, and
L Roncali, and
F Dammacco
May 2002,
Journal of pediatric hematology/oncology,
D Ribatti, and
A Vacca, and
M Iurlaro, and
R Ria, and
L Roncali, and
F Dammacco
January 1988,
Journal of acquired immune deficiency syndromes,
